Stockreport

Theravance Biopharma Announces First Subject Dosed in Phase 1 Study of TD-0903, in Development for the Treatment of Hospitalized Patients with Acute Lung Injury Caused by COVID-19

Theravance Biopharma, Inc. - Ordinary Shares  (TBPH) 
Last theravance biopharma, inc. - ordinary shares earnings: 2/24 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.theravance.com/investor-relations